Featured Opinions
What’s it going to take to ‘Rethink Pharma’?
by David Laws
What does that even mean? Patricia Seybold, Founder of Customers.com, once wrote “fasten your seatbelts!......Why? Because we’re in the midst of a profound revolution. And it’s bigger than the internet revolution or the mobile wireless revolution. It’s a customer revolution".
Huge Untapped Growth Potential of ASEAN
by Marc Yates
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Value-Added Services: The impact on the pharma business model
by David Laws
So what is stopping pharma from jumping wholeheartedly into providing value added services?
How Behavioral Economics Can Inform Adherence Interventions
Although future advances in population-wide health may well be driven less by new drugs and devices and more by behavior change, there is no denying that initiating and sustaining healthy behaviors can be very difficult.
Growth markets aren't the future for big pharma, but they could be for new business models and better patient outcomes.
Distribution of Sales and Marketing Spend Must Change
In recent years, pharma companies have reduced their cost base in response to decreasing revenues due in part to patent expirations and thin pipelines.
by Marc Yates
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
The power of observation in gathering patient insights
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
The Challenge of Engaging Patients to Engage
“Build it and they will come” is not a sound strategy for anything in healthcare.
Market Insights Can Deliver a Better Patient Experience
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
The Reputation Imperative: In Pharma We Trust?
One excuse for the lack of innovation within pharma is that it suffers from a bad reputation which inhibits trust among ‘gatekeeping’ stakeholders.
Are De Facto Price Controls Imminent?
By and large the pharmaceutical industry has escaped price controls in the US -- especially when compared to other markets around the world. Is this situation tenable, and if not, what will the implications be for the industry?
Which Is More Important for Commercial Success: First to Market or Best in Market?
Many of our Clients have been saying how hypercompetitive their markets have become. This is especially true in Diabetes with the newer classes as well as in Oncology, Cardiovascular and other therapy areas.
The Future of Pharma Sales: Part II
This month, Rita continues looking at the future sales rep, a role which must evolve in order to thrive in this new healthcare landscape.
Adherence: The Mother Lode of Value Added Services – Or Not?
by David Laws
This is the third in my series of articles about Value Added Services and no discussion on the topic would be complete without a deep dive into Patient Adherence. At least from a pharmaceutical company perspective.
Are You Clear About the Role of Marketing in Pharma?
Pharmaceutical marketers seem to be rapidly losing the ability to understand and influence their customers. For many years, Pharmaceutical marketers were blindsided by their own success and relied too strongly on innovative new products.
Is Pharma Branding at Odds with Patient Engagement?
Regular columist Katrina Firlik, MD, looks at the negative impact pharma branding can have on patient adherence programs.
Life: An Awfully Big Adventure
by Graham Young
This month Graham Young ruminates on the virtues of smoking too much, drinking too much and generally enjoying life too much - because, healthy living or not - life'll kill you in the end!
Patient Adherence & The Marshmallow Effect
by Kevin Dolgin
This month Kevin departs from the business end of patient support to examine an interesting cause of non-adherence among patients - The Marshmallow Effect.
This month Mary concentrates on one of the most oft-overlooked stakeholders in healthcare, the caregiver, and asks: for someone so integral to patient adherence and support, is there more we can do to provide care for the carer?
The Future of Pharma Sales: Part I
Manufacturers have been engaged in an “arms race” in which the number of “feet on the street” was the principal point of competition. A 1996 study even calculated that the volume of sales reps had surpassed the capacity of all physicians to see reps!
What’s The Difference Between Patient Centricity and Customer Focus?
by David Laws
This month David draws on his and our own experiences of past ‘centricity’ drives and asks: how can the industry avoid repeating the same past mistakes?
Ensure Your Marketing Creates Visible Financial Results for Your Company
We all know that the old model, in which Pharmaceutical companies flooded the market with sales reps and targeted individual prescribers, no longer works, so what now?
Maximizing the Use of YouTube in Pharma Communications
How can a Pharma company utilize YouTube to its advantage, building brands, increasing awareness, and ultimately boosting sales?
Key Considerations for Entering Into Risk Sharing
Imagine purchasing a new car or appliance only to learn that it doesn’t work as advertised and there’s nothing you can do about it. In most realms of commerce, if a product fails to deliver what’s been promised, consumers are financially covered through refunds and warranties.